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Introduction
Doxorubicin cardiotoxicity (doxorubicin, the antineo-
plastic drug efficient in treatment of leukaemia, lymphomas 
and sarcomas) is characterized by rapid evolution of cardiac 
failure imminent to doxorubicin (Dx) cardiomyopathy, in-
clusively at a young person, that is imposed as a cause of 
death or cessation of drug administration to oncologic pa-
tients. So, over several decades the researching of pathoge-
netical mechanisms of doxorubicin cardiomyopathy repre-
sents the main goal of cardiology and of course of oncology. 
Although many studies have been realized, till our days the 
pathophysiological prerogatives in conceptual plan have not 
been well established, the attempts to elaborate pathogenic 
therapy have at the base experimental values [1-3]. 
In this context, it is important to mention some success-
ful mechanisms:
1. Development of myocardial energy deficiency is 
caused by endangerment of mitochondrial respiration and 
of oxidative phosphorylation [4]. The depletion of ATP 
reserves directly correlates with the severity of contractile 
dysfunction of myocardium and inability of it to realize the 
heart adaptation to hemodynamic and neuroendocrine ef-
forts. A. Murabito et al. (2020) consider that doxorubicin 
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Abstract
Background: The cardiotoxicity of doxorubicin (Dx), an antineoplastic drug, is imposed by the development of cardiomyopathy and heart failure. 
The expression of endothelin-1 (ET-1) in myocardium under the action of Dx, directly correlates with the degree of cardiac dysfunction, mediated by 
endothelin A (ETA) receptor.  
Material and methods: For prospective randomized study 2 groups of white rats (experimental group n=9, control group n=9) were used. During 2 
weeks in the control group was administrated Dx (i/p, 4mg/kg in one dose, twice/week), cumulative dose – 16 mg/kg. The ET-1 effects were estimated 
at its peak action in concentration 10-7 M (mol), reproduced after 30 sec of endothelin stimulation. 
Results: The functional parameters of isolated heart perfused in physiologic regime and in condition of volume and resistance overload under the ET-1 
action in the group with Dx compared with the control one, were reduced considerably, namely: cardiac output (CO); left ventricle systolic pressure 
(LVSP); left ventricle end-diastolic pressure (LVEDP).
Conclusions: Under the ET-1 action on the isolated heart perfused in physiologic regime in the group with Dx – the LVSP and CO were reduced determining 
negative inotropic effect. At the volume overload test, under the ET-1 action, the diastolic impairment was more evident in the group with Dx, due to 
increased LVEDP. At the resistance overload test under the ET-1 action, the CO was reduced indicating the depreciation of myocardial contraction capacity.
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(Dx) is accumulated in cardiomyocyte and binds to one of 
the phospholipids of mitochondrial membrane, cardiolipin, 
that in turn affects the electron transport and increases the 
membrane permeability for cytochrome C, responsible for 
activation of caspase 9 and initiation of apoptosis process 
[5]. Moreover, Dx reduces the ratio Bcl2/Bax (cardiac anti- 
and proapoptotic factors).
2. The activation of oxidative stress is due to exagger-
ated production of reactive oxygen species and deprecia-
tion of antioxidant system. It has been established that ac-
cumulation of Dx into the mitochondria in concentration 
more than 100 µM, represents the threshold level for the 
onset of lipid and protein peroxidation in cardiomyocytes. 
The administration of antioxidants, such as vitamin C and 
coenzyme Q10, in the experimental model of Dx cardiomy-
opathy in rats, has shown the improvement of left ventricle 
function at the effort and resistance [6, 7]. 
3. The impairment ratio between collagen type I and 
type III, caused by extracellular matrix metalloproteinase 
activation, determines one of the causes of pathologic myo-
cardial remodeling with the eccentric pattern and dilation 
of left ventricle (LV), responsible for the disturbance of lusi-
tropy function of the heart [8]. The evaluation of circulating 
level of different types of metalloproteinases (e.g. MMP-2 
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and MMP-9) has the predictive value of the risk of extracel-
lular matrix remodeling of myocardium and exacerbation 
of heart failure. 
4. The activation of inflammatory response, according to 
the results of several fundamental researchers, is one of the 
important mechanisms leading to dysfunction of heart in-
clusively doxorubicin cardiotoxicity [9-11]. In this context 
X. Xinyong et al. (2020) have demonstrated the role of trans-
membrane receptors, Toll-like, in the onset of inflammatory 
response of cardiomyocyte and interstitial macrophage to 
the action of signal molecules derived from damaged car-
diac cells – Damage Associated Molecular Pattern (DAMP), 
resulting in increased production of cytokines [12]. The 
expression of Tumor Necrosis Factor-α (TNF-α) in murine 
myocardium subjected to action of Dx is increased in di-
rect ratio with the cumulative dose of anthracycline. In one 
of previous fundamental researches, we have demonstrated 
that administration of monoclonal antibody of TNF-α at-
tenuates the cardiotoxicity of doxorubicin, manifested by 
the improvement of inotropy of the heart [13].
5. The activation of neuro-endocrine system is charac-
terized by initial activation of sympathetic adrenal system 
followed by excessive synthesis of endothelin-1 (ET-1). The 
expression of ET-1 in myocardium subjected to action of 
doxorubicin (Dx) correlates directly with the severity of 
structural disturbances, remodeling and degree of cardiac 
dysfunction, effects of this oligopeptide is mediated by ETA 
receptor [14, 15]. The functional activity of ET-1 is char-
acterized by increasing concentration of calcium into the 
cardiomyocyte and smooth vascular muscle, which denotes 
the increased cardiac contraction and constriction of coro-
nary arterioles. Evidently, that inotropy stimulation of the 
myocardium requires also additional energy expenditure, 
which can compromise the heart adaptation to the action of 
stressful and effort factors, especially those, compared with 
catecholamine and angiotensin II (Ang II), the time of ET-1 
metabolisation is much longer. Furthermore, in the myo-
cardial interstitium there are granules that can store ET-1 
formed by endothelial coronary and cardiac cells and which 
are realized in huge amount at the paracrine and endocrine 
actions, triggered by hypoxia, ischemia, energy depletion, 
oxidative stress, etc. Thus, ET-1 imposes notable pathoge-
netic contribution in the onset and exacerbation of cardiac 
failure, but the particularities of its action on the heart func-
tionality in doxorubicin affection are still poorly explained.
Material and methods
The doxorubicin cardiomyopathy of the heart has been 
reproduced on the white rats by administration of Dx in-
traperitoneal (cumulative dose 16 mg/kg during 2 weeks, 2 
injections/per week in one dose 4.0 mg/kg). Rats have been 
sacrificed by euthanasia (thiopental sodium, 0.4 mg/kg) af-
ter 10 days from the last injection of anthracycline, because 
doxorubicin is a drug that due to reduced clearancei s ac-
cumulated in the body.
The isolated heart has been perfused in working regime 
according to the Neely-Rovetto method, functional indices 
of left ventricle (LV) were estimated by the technical reg-
istration device of the parameters in real time “Bio-Shell” 
(Australia) or by recorder Linearcorder Mark WR3101 
(Germany) connected to mechanical sensor. 
The effort reactivity of the heart has been studied by the 
increasing filling pressure of the left atrium to the value of 
25cm H2O (volume overload) or of the pressure in aorta to 
the value of 120 cm H2O (volume overload). The effects of 
endothelin-1 (ET-1) were estimated at the peak of its action 
in concentration of 10-7 M (mol) or, when the action of ET-1 
during 30 sec on the isolated heart preceded the manoeu-
vres of volume and resistance overload. At the same time, 
the premedication of isolated isovolumic heart with ET-1 
in concentration of 5x10-7 M during 30 sec, gave the oppor-
tunity to appreciate the impact of ET-1 on the myocardium 
tolerance to ischemia-reperfusion stress (30 min ischemia 
and 45 min reperfusion).
The obtained data exposed by value of M±m (mean and 
standard error) were compared and statistically analysed ac-
cording to t-Student criteria in relation to the records of the 
control group (intact rats) or in relation with indices esti-
mated before the effort test. Margin of error less than 5 % 
was considered admissible, but deviation from the reference 
value – statistically significant (p<0.05).
Results
The estimation of functional indices of isolated heart in 
condition of physiologic effort perfusion (pressure in the 
left atrium and aorta is 15 and respectively, 80 cm H2O) al-
ready has shown serious dysfunction of left ventricle (LF) in 
the group with doxorubicin (tab. 1).
Table 1
The values of functional indices of isolated heart 








Aortic jet velocity (AJ), ml/min 21.5±1.4 12.8±0.8
-40.47%
<0.01
Cardiac Output (CO), ml/min 37.4±1.9 23.6±1.3
-36.90%
<0.01
Left ventricular systolic pres-




Heart rate (HR), 1/min 289±13 245±11
-15.22%
<0.05
Left ventricular enddiastolic 









+dP/dTmax, mm Hg/sec 8565±208 6320±165
-26.21%
<0.05
-dP/dTmax, mm Hg/sec 6710±174 5045±120
-24.81%
<0.05
Note: p – value of significance vs control; ± – relative deviation from the 
control group. 
45
oriGiNal  research L. Tacu. Moldovan Medical Journal. October 2020;63(4):43-48
So, the main indices of pumping function of left ventricle 
(AJ and CO) are by 40.47% reduced from the control group, 
but systolic pressure generated by LV reaches the averages 
of 75% from control values of parameter. Also, is remarked 
the evident decline of diastolic relaxation of LV, being given 
increased LVEDP and diastolic stiffness by 168% and, re-
spectively 109.73%. 
Also, it is attested the disturbance of contraction and 
isovolumetric relaxation of the heart, and main parameters 
that characterized these important phases of cardiac cycle 
(e.g. +dP/dTmax and -dP/dTmax) are decreased signifi-
cantly by 26.21% and respectively 24.81% compared with 
the control group.
There are important evidences that reflect the inotropy 
response of isolated heart perfused in physiologic regime 
under the action of ET-1 (tab. 2).
Table 2
The values of functional indices of isolated heart 
perfused in physiologic regime under the action of ET-1
Indices/lot Action ET-1 (10-7 М)




































Note: * - p<0.05 vs control
The obtained results describe 3 important features: 
First of all, inotropic response of the heart in the doxo-
rubicin disorder is compromised. Unlike the control heart, 
it is manifested by the positive inotropic effect, being given 
by the increased value of left ventricular systolic pressure 
(LVSP) at the peak of stimulation by 25.1%, but in the Dx 
group it has been reduced by 9.1% that denotes the nega-
tive inotropic effect. As a result, cardiac output increased in 
case of positive inotropic effect with the ratio of 15.7%, but 
decreased cardiac output (CO) compared with initial value 
– by 9% that is characteristic for negative inotropic effect.
Secondly, ET-1 has increased the diastolic rigidity in 
both groups, fact that explains the imminent effect of this 
oligopeptide for increasing the concentration of calcium 
in cardiomyocyte, but unlike catecholamines it doesn’t 
stimulate analogical lusitropy function of the myocardium. 
However, in the group of Dx the value of left ventricular 
enddiastolic pressure (LVEDP) has increased more at the 
peak of stimulation by about 70% compared with the con-
trol one: 41.6% vs 24.5%.
Thirdly, for the action of ET-1 it is not characteristic the 
notable chronotropic effect, but heart rate (HR) increased 
up to 4.6% from the initial values, both in the control and 
the Dx groups.
The detrimental effects of ET-1 have been manifested es-
pecially in the context of adaptive processes of the heart in 
the condition of volume and resistance effort, because both 
tests require from the heart the engaging of intrinsic mecha-
nisms of contraction and relaxation capacity.
The premedication of the isolated heart with ET-1 has 
reduced the increasing rate of CO in the condition of in-
creasing left atrial pressure up to 25 cm H2O (tab. 3).
Table 3
ET-1 effect on the adaptive capacity of the isolated heart 
in the condition of effort with volume overload
Indices
Effort with volume over-
load without ET-1 (n=9)
Effort with volume 
overload preceded by 
ET-1 (n=9)























Note: +% – relative increment vs initial index; p – significance vs control
At effort test with volume overload of LV, the cardiac 
output and LVEDP are the main important parameters that 
estimate functional feasibility of the heart for adaptive proc-
esses. According to the physiologic entity of the test with 
volume overload, the values of these indices are increased 
in both groups. So, CO has increased in the control group 
by 47.43%, but in the group of Dx the rate of rise was lower 
– 37.71%. On the other hand, elevation of control LVEDP 
came to 38.78%, but in doxorubicin affection it was consid-
erably more – 54.4%, that indicates the depreciated diastolic 
relaxation capacity.
In case of premedication with ET-1 the heart response 
was limited, especially in the group with Dx. The increas-
ing rate of CO has been reduced by 43.8% (from 37.71 up 
to 21.19%), while in the control group it decreased only by 
17.73% (from 47.43% up to 39.02%). This phenomenon is 
determined by the more pronounced alteration of diastole by 
ET-1 in the Dx group, because LVEDP increased by 98.4%, 
while in the control group the increasing of this index was 
53.06%. As a result, the absolute mean value of LVEDP in 
doxorubicin disorder has become above 3.3 times greater 
than that from the control group (24.8 vs 7.5 mm Hg).
46
oriGiNal  researchL. Tacu. Moldovan Medical Journal. October 2020;63(4):43-48
Premedication of the heart with ET-1 has compromised 
essentially the adaptive ability in the condition of increas-
ing peripheral resistance by elevation pressure in aorta up 
to 120 mm Hg (tab. 4).
Table 4
Effect of ET-1 on the isolated heart adaptation in the 
condition of effort with resistance
Indices
Effort with resistance 
without  ET-1
































Note: +% – relative increment vs initial index; p – significance vs control
The increasing rate of LVSP in the condition of effort 
with resistance without ET-1 premedication didn’t differ 
considerably in both groups (from 20.4% in Dx up to 22.9% 
in the control group), although the recoil of absolute index 
compared with the control one was considerable, 28.4% 
(126.3±11.5 vs 176.4±11.3 mm Hg).
When the test with effort and resistance was reproduced 
under the action of ET-1, the contraction capacity of the 
myocardium in the Dx group reduced more considerably. 
So, the increasing rate of LVSP in the control group depre-
ciated from 22.9% to 20.4%, but in the Dx group – from 
20.42% to 6.29%. In this context it is mentioned that the dif-
ference of absolute value of LVSP increased from 28.4% up 
to 35.47%.
The disturbance of heart contractility under the action 
of ET-1 in the Dx group manifested by decreasing much 
more significantly CO at elevation of pressure in aorta. So, 
depreciation of CO in the control group was 52.08%, but in 
doxorubicin disorder – 51.7%. As a result, the cardiac out-
put in the Dx group was depreciated by 55.12% compared 
with control index.
Therefore, the ET-1 action has manifested the negative 
inotropic effect in doxorubicin disorder of the heart and has 
been imposed by the exhaustion of adaptive capacity of the 
myocardium in the condition of effort with volume and re-
sistance.
Premedication with ET-1 depreciated more notably the 
heart tolerance in the Dx group compared to the control 
one, at the action of ischemia (30 min), as so reperfusion 
(45 min), attested by the evaluation of enddiastolic pressure 
of LV (tab. 5).
The LVEDP value at 30 min action of ischemia has in-
creased by 21.2% in the Dx group, in case the premedication 
of isovolumic heart with ET-1. It is important to mention 
that in the control group the elevation of LVEDP in simi-
lar condition constituted only 11.8%. So, ET-1 increased the 
difference of LVEDP between the Dx and the control groups 
from 52.76% up to 65.67% that was appreciated at 30 min 
of ischemia action. ET-1 affects the functional recovery of 
myocardium after reperfusion in both groups, being given 
elevation of LVEDP.  However, the rising of this index was 
greater in the Dx group: 56.6 vs 35.6%. As a result, the value 
LVEDP estimated at 45 min of reperfusion increased in the 
Dx group compared with the control one by 76.73% (initial 
increment constituted 53.02%).
Discussion
The repeated action of doxorubicin in cumulative dose 
of 14 mg/kg during 14 days leads, in our study, to the myo-
cardial contractility disturbance, especially in effort test 
with resistance, manifested by increasing decline of cardiac 
output and systolic pressure of LV compared with the con-
trol group. Impairment of pumping function of LV explains 
the phenomena of doxorubicin cardiotoxicity.
The recent reported data have shown that Dx can induce 
sarcopenia caused by disturbed synthesis of sarcomere con-
tractile proteins, and concomitantly with detrimental effect 
on ATP synthesis, it can be a serious cause of functional in-
competence of heart for adaptation to hemodynamic and 
neuroendocrine efforts [16, 17]. The action of ET-1 on the 
isolated heart perfused in physiologic regime has manifest-
ed in the group with Dx by decreasing of systolic pressure 
of left ventricle and of cardiac output at the peak of stimula-
tion, that from pathophysiologic point of view is described 
as negative inotropic effect.
Endothelin-1 (ET-1), as angiotensin II (Ang II) or 
adrenergic agonists, is one of the important natural stimu-
lators of myocardial inotropy, which in the control group 
has been imposed by elevation of LVSP, followed by increas-
ing of aortic jet velocity and cardiac output. The negative 
inotropic effect specific for ET-1 can be recorded as nota-
ble pathogenetic mechanism of onset and exacerbation of 
Table 5
Value LVEDP of isovolumic heart in ischemia and 
reperfusion

































Note: p1 – significant vs index before ET-1 action; p2 – significant vs 
control 
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heart failure in patients with doxorubicin cardiomyopathy, 
because hemodynamic effort or homeostasis disturbances 
(e.g. hypoxia, ischemia, oxidative stress, augmentation of 
immune-inflammatory response, hyperglycemia, acidosis, 
etc.) lead to excessive realizing of ET-1.
A. Luu et al. (2018) consider that limitation of endothe-
lial dysfunction is a conclusive benefit in doxorubicin disor-
der of the myocardium, due to limitation of the factors that 
stimulate realizing of ET-1, or by the factors that decrease 
detrimental effect of it, such as nitric oxide, prostacyclin, 
antioxidant enzymes, etc [18]. In pathophysiology of doxo-
rubicin cardiomyopathy, endothelin 1 is viewed as neuroen-
docrine factor with mitogenic properties, such as growth 
factor, prooxidant, proinflammatory, etc.
Through the mechanisms of negative inotropy of ET-1in 
Dx affection can be underlined the coronaroconstriction 
action superior to reactivity of the intact heart, demon-
strated in recent researches [19]. The diminished coronary 
functional reserve increases energy depletion and cardio-
myocyte overloading with calcium that is detrimental to 
diastolic relaxation and realizing of Starling law. The effect 
of cardiomyocyte overload with calcium, specific for doxo-
rubicin cardiotoxicity has been demonstrated by us through 
decreasing of myocardial tolerance to the ischemia-reper-
fusion impact [13].
It is remarkable that premedication of the isolated heart 
with ET-1 even 30 sec before the hemodynamic effort, lim-
ited the adaptive-compensatory capacity, in this way under-
lining the role of diastolic relaxation disturbance in hetero-
metric regulation of heart in volume overload, as the role of 
compromised myocardial inotropy in homeometric regula-
tion of heart in resistance overload.
The obtained data indicate the key mechanisms of di-
astolic and systolic disturbance in doxorubicin disorder, 
these being determined by significant decreasing the veloc-
ity of relaxation(-dP/dTmax) and isovolumetric contrac-
tion (+dP/dTmax) of the heart. The functional component 
of these phases is orchestrated mainly by the energetic po-
tential, necessary for adequate turnover of the calcium cati-
ons, and it is dominant in the intrinsic system of the heart, 
such as: (1) increasing cardiac output in heart overload with 
volume by the formation of filling pressure for realizing 
Starling mechanism; (2) reaching the “mechanical stress”, 
by the accumulated kinetic energy, sufficiently to overcome 
increased peripheral resistance in effort with resistance.
In estimation of functional severity and prognostic of 
heart failure, the values, such as isovolumic relaxation time 
and isovolumic contraction time of the heart are used as 
variables for echocardiographic appreciation of Tei index, 
considered as an index of precocious evaluation of cardiac 
dysfunction based on reduced ejection time of LV, due to 
increasing relaxation time and isovolumic contraction time, 
or decreasing values +dP/dTmax and -dP/dTmax [20].
W. Border et al. (2020) consider in this context that 
echocardiographic indices of isovolumic relaxation and 
contraction of the heart are important functional predictors 
of precocious heart disorders in oncologic children who take 
anthracycline [21]. Thus, the effort tests which underline 
the functional dysregulation of isovolumic relaxation and 
contraction of the heart, which are absent in rest condition, 
have a great diagnostic value in doxorubicin cardiotoxicity.
The drugs that modulate activity of ET-1 (nonspecific 
blockers of receptors ETA/ETB and inhibitory of ET-1 con-
version enzyme) are used in the treatment of cardiac failure, 
and especially in pulmonary arterial hypertension, in which 
pathogenesis of the ET-1 has crucial role, promoting the von 
Euler reflex [22, 23]. So, it is a great benefit for modulation 
the activity of ET-1 in patients who administrate doxoru-
bicin, especially due to the fact that the level of circulated 
ET-1 elevates with increasing cumulative dose of Dx and 
directly correlates with severity of injury and cardiac dys-
function [24].
Conceptually the ET-1 effect is important for reducing 
myocardial tolerance under the action of ischemia-reper-
fusion syndrome. The impact of this is imposed by cardio-
myocyte overload with calcium and excessive realizing of 
oxygen free radicals. The premedication of the heart with 
ET-1 potentiated these mechanisms and in such a way lim-
ited the capacity of intrinsic system of the myocardium to 
diminish impact of calcium overload and oxidative stress. 
It is important to mention, in this context, that myocardial 
ischemia increases the level of ET-1 realized by interstitial 
granules and expression of vasoconstrictor receptors [25]. 
On the other hand, cardiotoxicity of Dx also is imposed by 
the increasing ET-1 expression and disturbance of coronary 
reactivity depending on the endothelium [13]. Another 
mechanism is determined by the decreasing expression of 
NO under the action of ET-1, that compromises myocardial 
resistance to ischemic reperfusion impact [26].
Conclusions
Cardiotoxicity of doxorubicin is characterized by sig-
nificant decreasing of contraction and relaxation velocities 
of left ventricle, as well as by negative inotropy effect under 
the ET-1 action in vitro, which disturbs heterometric and 
homeometric cardiac regulation, and myocardial tolerance 
to ischemia and reperfusion.
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